RxDoctor Payments Data

Jamie Brown

Nurse Practitioner · Kittanning, PANPI 1770074783

Payments from drug & device makers

$2,879in general payments, 2019–2025

Across 80 payments — averaging $35.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mid-atlantic Surgical Systems, LLC$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$384
  • Stryker$254
  • Boston Scientific$147
  • E.r. Squibb & Sons, L.L.C.$145
  • Johnson & Johnson$130
  • plus $603 from 11 others

What the payments were for

  • Food & beverage$1,67958%
  • Education$1,20042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,879 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,345
Medicare patients
121
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban674$580,280
XareltoRivaroxaban216$197,301
EntrestoSacubitril/Valsartan157$148,964
Repatha SureclickEvolocumab65$43,368
BrilintaTicagrelor72$39,072
JardianceEmpagliflozin34$31,265
FarxigaDapagliflozin Propanediol40$25,707
Metoprolol Succinate558$9,114
Atorvastatin Calcium540$8,047
Propafenone Hcl ErPropafenone Hcl35$7,621
Valsartan223$5,711
Ranolazine ErRanolazine96$5,646
Amiodarone Hcl101$4,215
Ezetimibe161$3,837
Rosuvastatin Calcium203$3,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$130$197,301216 claims
NovartisEntresto$123$148,964157 claims
AstraZenecaBrilinta, Farxiga$87$64,780112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Kittanning

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →